{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:50:39Z","timestamp":1787061039322,"version":"build-2736575974"},"reference-count":78,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T00:00:00Z","timestamp":1151020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p>Important progress has been made in our understanding of the cellular and molecular processes underlying the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert\u2013Eaton myasthenic syndrome (LEMS) and neuromyotonia (peripheral nerve hyperexcitability; Isaacs syndrome). To prepare consensus guidelines for the treatment of the autoimmune NMT disorders. References retrieved from MEDLINE, EMBASE and the Cochrane Library were considered and statements prepared and agreed on by disease experts and a patient representative. The proposed practical treatment guidelines are agreed upon by the Task Force: (i) Anticholinesterase drugs should be the first drug to be given in the management of MG (good practice point). (ii) Plasma exchange is recommended as a short\u2010term treatment in MG, especially in severe cases to induce remission and in preparation for surgery (level B recommendation). (iii) Intravenous immunoglobulin (IvIg) and plasma exchange are equally effective for the treatment of MG exacerbations (level A Recommendation). (iv) For patients with non\u2010thymomatous autoimmune MG, thymectomy (TE) is recommended as an option to increase the probability of remission or improvement (level B recommendation). (v) Once thymoma is diagnosed TE is indicated irrespective of the severity of MG (level A recommendation). (vi) Oral corticosteroids is a first choice drug when immunosuppressive drugs are necessary in MG (good practice point). (vii) In patients where long\u2010term immunosuppression is necessary, azathioprine is recommended together with steroids to allow tapering the steroids to the lowest possible dose whilst maintaining azathioprine (level A recommendation). (viii) 3,4\u2010diaminopyridine is recommended as symptomatic treatment and IvIg has a positive short\u2010term effect in LEMS (good practice point). (ix) All neuromyotonia patients should be treated symptomatically with an anti\u2010epileptic drug that reduces peripheral nerve hyperexcitability (good practice point). (x) Definitive management of paraneoplastic neuromyotonia and LEMS is treatment of the underlying tumour (good practice point). (xi) For immunosuppressive treatment of LEMS and NMT it is reasonable to adopt treatment procedures by analogy with MG (good practice point).<\/jats:p>","DOI":"10.1111\/j.1468-1331.2006.01476.x","type":"journal-article","created":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T09:45:45Z","timestamp":1151055945000},"page":"691-699","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Guidelines for the treatment of autoimmune neuromuscular transmission disorders"],"prefix":"10.1111","volume":"13","author":[{"given":"G. O.","family":"Skeie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Apostolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. E.","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. K.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hilton\u2010Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Melms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W.","family":"Horge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00867.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri916"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/85520"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05440.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320419"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939509001933"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1999.650555.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197611020-00002"},{"key":"e_1_2_6_10_2","first-page":"145","article-title":"Air\u2010flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air\u2010flow limitation","volume":"130","author":"Szathmary I","year":"1984","journal-title":"The American Review of Respiratory Disease"},{"key":"e_1_2_6_11_2","first-page":"618","article-title":"Air\u2010flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air\u2010flow limitation","volume":"128","author":"Shale DJ","year":"1983","journal-title":"The American Review of Respiratory Disease"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00833919"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90025-I"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389601100608"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.11.1596"},{"key":"e_1_2_6_16_2","first-page":"CD002275","article-title":"Plasma exchange for myasthenia gravis","volume":"4","author":"Gajdos P","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb33769.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880030603"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb33770.x"},{"key":"e_1_2_6_20_2","first-page":"939","article-title":"Long\u2010term effects of plasma exchange in myasthenia. Results of a randomized study","volume":"12","author":"Gajdos P","year":"1983","journal-title":"Presse Medicale"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92294-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B"},{"key":"e_1_2_6_23_2","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"2","author":"Gajdos P","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197610000-00008"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-002-0037-x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.7"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00209.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg223"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200010)48:4<603::AID-ANA6>3.0.CO;2-1"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10665"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200406000-00008"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150615"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)05370-7"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10133"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161205"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-8411(92)90048-U"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_2_6_42_2","first-page":"341","article-title":"Treatment of severe myasthenia gravis with cyclosporin. A 12\u2010month open trial","volume":"18","author":"Goulon M","year":"1989","journal-title":"Presse Medicale"},{"issue":"4","key":"e_1_2_6_43_2","first-page":"211","article-title":"Results of a one\u2010year open trial of cyclosporine in ten patients with severe myasthenia gravis","volume":"20","author":"Goulon M","year":"1988","journal-title":"Transplantation Proceedings"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050141"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.3.448"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.97"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.94"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1159\/000050768"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.912-a"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004691-200309000-00011"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200008)23:8<1287::AID-MUS22>3.0.CO;2-L"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094122.88929.0B"},{"key":"e_1_2_6_53_2","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1016\/S0021-9258(19)49416-7","article-title":"The calcium release channel of sarcoplasmic reticulum is modulated by FK\u2010506\u2010binding protein. Dissociation and reconstitution of FKBP\u201012 to the calcium release channel of skeletal muscle sarcoplasmic reticulum","volume":"268","author":"Timerman AP","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000125254.99397.68"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10472"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1054\/jocn.2001.0907"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10018"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00300-7"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1732"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100034077"},{"key":"e_1_2_6_61_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0003-9993(23)00011-4","article-title":"Physical training effects in myasthenia gravis","volume":"74","author":"Lohi EL","year":"1993","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000082725.21444.EC"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92652-6"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2005.01.002"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.447"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.85"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.6.766"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.10.018"},{"key":"e_1_2_6_69_2","first-page":"CD003279","article-title":"Treatment for Lambert\u2010Eaton myasthenic syndrome","volume":"2","author":"Maddison P","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912073212303"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)76153-5"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf178"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410215"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/116.2.453"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.12.2417"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00407-X"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380505"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(00)00093-7"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.102004271.x"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2006.01476.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2006.01476.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T09:12:20Z","timestamp":1696929140000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2006.01476.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,23]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1468-1331.2006.01476.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01476.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,23]]},"assertion":[{"value":"2006-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}